SAM
CORT icon

Sawgrass Asset Management’s Corcept Therapeutics CORT Stock Holding History

Sawgrass Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,655
Closed -$279K – 174
2020
Q4 		$279K Buy
+10,655
New +$224K 0.02% 135

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sawgrass Asset Management's CORT Position: Q1 2021 in Review

Sawgrass Asset Management sold out of Corcept Therapeutics (CORT) in Q1 2021, closing a stake of 10,655 shares — an estimated $279K sold.

Sawgrass Asset Management first reported a position in CORT in Q4 2020 and held it in 1 quarter. The position peaked at $279K in Q4 2020. 209 funds tracked by Wall St. Rank hold CORT as of Q1 2021.

  • Sawgrass Asset Management reported no remaining Corcept Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Sawgrass Asset Management sold 10,655 Corcept Therapeutics shares in Q1 2021, an estimated $279K.
  • Sawgrass Asset Management first reported a position in Corcept Therapeutics in Q4 2020 and held it in 1 quarter.
  • Sawgrass Asset Management's Corcept Therapeutics position peaked at $279K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2021.

Based on Sawgrass Asset Management's 13F filing for Q1 2021, filed 29 Apr 2021.